Glenmark Pharmaceuticals has launched GLIPIQ (semaglutide) in India for the management of Type 2 Diabetes Mellitus (T2DM), with a clear focus on improving affordability and access to advanced therapies. The product has received approval from the Central Drugs Standard Control Organisation (CDSCO) following a Phase III clinical study conducted in India to evaluate its efficacy and safety.
GLIPIQ is positioned as a cost-effective GLP-1 receptor agonist, addressing a key barrier in diabetes care – delayed initiation of injectable therapy due to high costs and complexity. With an expected weekly treatment cost ranging between Rs 325 and Rs 440, the drug aims to make GLP-1 therapy more accessible to a wider patient base.
The product is available in two formats: vial-based and pre-filled pen. The vial format, accompanied by dose-specific syringes, is designed to support physician-guided dosing, particularly during the early stages of treatment. Meanwhile, the pre-filled pen offers convenience for self-administration, catering to long-term patient use. Both formats are offered in multiple strengths, including 2 mg/1.5 mL, 4 mg/3 mL, and 8 mg/3 mL.
To further support patients, Glenmark has introduced ‘Sankalp’, a programme aimed at facilitating therapy initiation and improving adherence over time. Semaglutide, the active ingredient in GLIPIQ, is widely used in managing Type 2 diabetes, especially in patients with comorbidities such as obesity, cardiovascular disease, and chronic kidney disease.
With this launch, Glenmark seeks to broaden access to advanced diabetes treatment and encourage earlier intervention across India.
